Polifarma S.p.a.

Eniricerche S.p.a.

Other

Enichem Elastomeri S.p.a.

Vincenzo Politi

Giovanni Di Stazio

Giovanna De Luca

Mario Materazzi

Andrea Margonelli

Antonio S Verdini

Alessandro Sisto

Antonino Virdia

Silvana D'Alessio

Cinzia Piazza

Valerio Caciagli

Cesare Giordano

Maurizio Cirilli

Giovanna DeLuca

Giovanni DiStazio

Gabriella Panini

Mario Materazzi, Deceased

Antonio Sella

Mario Paglialunga Paradisi

Antonio Virdia

Giorgio Pochetti

Carlo Gallina

Barbara Gorini

Enrico Gavuzzo

Fernando Mazza

Metalloproteinase inhibitors, their therapeutic use and process for the production of the starting compound in the synthesis thereof

Peptidomimetic compounds capable of inhibiting zinc-dependent metalloproteinases to treat pathological conditions associated with activation of endogenous metalloproteinases in mammals.

Inhibitor compounds of zinc-dependent metalloproteinases associated with

Uridine is a therapeutic agent active as a growth promoter for treatment of neuron degenerative diseases deriving from pathological ageing or selective destruction, in particular Uridine shows the same biological effects as NGF, when added at low doses to the culture medium, so that uridine may replace NGF as therapeutic agent in neural diseases and it may be also associated with other growth factors that allow differentiation of neurons, or with anti-cancer and anti-virus drugs that cause neuron damage. In addition uridine shows important trophic properties on various types of cultured cells, stimulating cell reproduction when used at rather high dose levels.

Therapeutic active agent for treatment of neuron degenerative diseases

Compounds of general formula A--B--C in which: A is a monovalent radical of a L-ring molecule; B is a bivalent radical of a L-.alpha.-aminoacid; and C is a monovalent radical of a L-aromatic molecule. The compounds show an anti-hypertensive, analgesic, immuno-modulating and antiinflammatory activity, they are resistant to enzyme hydrolysis and they can be used for the preparation of drugs for oral administration.

Peptide compounds of (L) amino acids and ring molecules, and

Compounds of general formula A--B--C in which: A is a monovalent radical of a laevorotatory ring molecule; B is a bivalent radical of a laevorotatory .alpha.-aminoacid; and C is a monovalent radical of a laevorotatory aromatic molecule. The compounds show an anti-hypertensive, analgesic, immuno-modulating and antiinflammatory activity, they are resistant to enzyme hydrolysis and they can be used for the preparation of drugs for oral administration.

Compounds with a sequence of three radicals, the central one being .alpha.-

3-indolepyruvic acid is an active agent in preventing cerebral damage caused by stress and ageing and induced by an excessive presence in the blood of glucocorticoids, secreted by the adrenal gland.

Method for reducing the level of glucocorticoids in the blood and

3-indolepyruvic acid derivatives substituted on the benzene moiety show good antagonizing activity on excitatory aminoacids and on free radicals, for which reason they are therapeutic agents in cerebral and peripheral degenerative pathologies. Their method of production by passage through the corresponding substituted triptophane.

Tryptophane and 3-indolepyruvic acid, methods of production therefor

Uridine is used to treat the peripheral complications of diabetes, such as neuropathy, retinopathy and vasculopathy, thanks to its characteristics of promotor of glycogen endocellular biosynthesis. 40 diabetic patients were treated for six months with uridine or with placebo in a double-blind clinical teat.

Use of uridine in the pharmacological treatment of the peripheral

A description is given of the cosmetic use of 3-indolepyruvic acid for the protection of the skin from damage caused by oxygen, by the sun and by aging.

Cosmetic use of 3-indolepyruvic acid

Indolepyruvic acid shows an inhibitory activity with respect to the degenerative action by oxygen free radical which are responsible for a number of pathologic conditions in various peripheral tissues. The compound can find application in miocardiopathies, inflammations, circulatory shock, arteriosclerosis, and cardiac ischemia.

Use of 3-indolepyruvic acid as a pharmaceutical agent for the inhibition

Tripeptides having hypotensive activity, defined by the following general formula:

Tripeptide compounds having hypotensive activity

3-indolepyruvic acid derivatives and pharmaceutical use thereof

Disorders due to an altered balance of dopamine release by the cerebral dopaminergic system, such as schizophrenia and Parkinson's disease, can be treated by administration of uridine which is a specific agent for the protection of the cholecystokinin level in the brain tissue.

Pharmacological use of uridine in the treatment of nervous disorders

New decapeptides having hypotensive action are disclosed, which can be defined by the formula:

Growing community of inventors

Rome, Italy

Vincenzo Politi